These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17395338)

  • 1. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
    Halloran ME; Piedra PA; Longini IM; Gaglani MJ; Schmotzer B; Fewlass C; Herschler GB; Glezen WP
    Vaccine; 2007 May; 25(20):4038-45. PubMed ID: 17395338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures.
    Halloran ME; Longini IM; Gaglani MJ; Piedra PA; Chu H; Herschler GB; Glezen WP
    Am J Epidemiol; 2003 Aug; 158(4):305-11. PubMed ID: 12915495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler G; Riggs M; Griffith M; Fewlass C; Watts M; Hessel C; Cordova J; Glezen WP
    Vaccine; 2005 Feb; 23(13):1540-8. PubMed ID: 15694506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.
    Gaglani MJ; Piedra PA; Herschler GB; Griffith ME; Kozinetz CA; Riggs MW; Fewlass C; Halloran ME; Longini IM; Glezen WP
    Arch Pediatr Adolesc Med; 2004 Jan; 158(1):65-73. PubMed ID: 14706961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J; Ambrose CS; Dickinson S; Hamilton H; Oleka NA; Malinoski FJ; Wittes J
    Vaccine; 2009 Feb; 27(7):1101-10. PubMed ID: 19095024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB; Gruber WC
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1947-51. PubMed ID: 11779396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.
    McLean HQ; Caspard H; Griffin MR; Gaglani M; Peters TR; Poehling KA; Ambrose CS; Belongia EA
    JAMA Netw Open; 2018 Oct; 1(6):e183742. PubMed ID: 30646262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.
    Ambrose CS; Wu X; Knuf M; Wutzler P
    Vaccine; 2012 Jan; 30(5):886-92. PubMed ID: 22155144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
    Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
    Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.
    Vesikari T; Fleming DM; Aristegui JF; Vertruyen A; Ashkenazi S; Rappaport R; Skinner J; Saville MK; Gruber WC; Forrest BD;
    Pediatrics; 2006 Dec; 118(6):2298-312. PubMed ID: 17142512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
    Nichol KL; Mendelman PM; Mallon KP; Jackson LA; Gorse GJ; Belshe RB; Glezen WP; Wittes J
    JAMA; 1999 Jul; 282(2):137-44. PubMed ID: 10411194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
    Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
    Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.